March 30, 2017 / 5:17 PM / in 5 months

BUZZ-Acasti Pharma Inc: To proceed with late-stage study of metabolic disorder drug

** Drugmaker's U.S.-listed shares rise as much as 31 pct to a 2-month high of $1.65

** To proceed with late-stage study of CaPre, its treatment for hypertriglyceridemia, a metabolic condition that contributes to risk of cardiovascular disease and pancreatitis; study to begin late 2017

** Says U.S. Food and Drug Administration feedback supports plan for two studies instead of one large study, potentially shortening its marketing application time

** More than 980,000 shares traded, 10.2x 30-day moving avg

** Up to Wednesday's close, stock had fallen 15 pct in the last 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below